All patients must be willing to undergo a mandatory bone marrow aspirate and/or biopsy at baseline for the assessment of biomarker/pharmacodynamics and disease status
You may not be if
Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of either study drug
Radiotherapy within 14 days before the first dose of either study drug except localized radiation therapy for lytic bone lesions and plasmacytomas
Major surgery within 2 weeks before the first dose of either study drug
Ongoing therapy with chronic or high dose corticosteroids. Low dose steroids (i.e. prednisone ≤ 10 mg or an equivalent steroid dose), inhaled and topical steroids are permitted
Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment:
Narrow Therapeutic index substrates, strong inhibitors and strong inducers of CYP3A4
Strong Inhibitors of CYP2D6
Narrow therapeutic index substrates of CYP2C8, CYP2C9, CYP2C19 and CYP2D6
Any of the following clinical laboratory results during screening (i.e., within 28 days before the first dose of either study drug):
Absolute neutrophil count (ANC) \< 1,000/mm3 without growth factor support within 7 days prior to testing
Platelet count \< 75,000 mm3 without transfusion support within 7 days prior to testing
Bilirubin \> 1.5 times the upper limit of the normal range (ULN).
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the ULN.
Calculated creatinine clearance \< 30 ml/min according to Cockcroft-Gault equation
Corrected QT interval (QTc) of \> 450 milliseconds (ms) in males and \> 470 milliseconds (ms) in females on baseline electrocardiogram (ECG) (using Fridericia \[QTcF\] corrected QT interval
